Trade Panel Bolsters FDA's View In Amarin Omega-3 Complaint

International Trade Commission won't investigate Amarin's complaint that some dietary supplements containing omega-3 formulations similar to icosapent ethyl in its Vascepa are actually drugs and should be blocked from import into US, likely discouraging others from this novel approach.

US International Trade Commission ITC in Washington DC

The International Trade Commission agrees it's FDA's job to regulate the dietary supplement industry as it rejects Amarin Corp. PLC's fair trade complaint alleging some omega-3 ingredients are unapproved new drugs.

The attempt by Amarin to eliminate competition for its Rx drug Vascepa from some omega-3 dietary supplements likely now won't...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America